Literature DB >> 20695977

rFVIIa transported from the blood stream into tissues is functionally active.

R Gopalakrishnan, U Hedner, C Clark, U R Pendurthi, L V M Rao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20695977      PMCID： PMC4472316          DOI： 10.1111/j.1538-7836.2010.04010.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  11 in total

1.  Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint.

Authors:  B R Saxon; D Shanks; C B Jory; V Williams
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

2.  Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors.

Authors:  J Blatny; S Kohlerova; O Zapletal; V Fiamoli; M Penka; O Smith
Journal:  Haemophilia       Date:  2008-06-05       Impact factor: 4.287

3.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.

Authors:  J H Morrissey; B G Macik; P F Neuenschwander; P C Comp
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

4.  Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.

Authors:  G Young; M McDaniel; D J Nugent
Journal:  Haemophilia       Date:  2005-05       Impact factor: 4.287

5.  Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.

Authors:  W Y Tcheng; J Donkin; S Konzal; W-Y Wong
Journal:  Haemophilia       Date:  2004-05       Impact factor: 4.287

6.  Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).

Authors:  R Gopalakrishnan; U Hedner; S Ghosh; R C Nayak; T C Allen; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

7.  Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.

Authors:  Natascha C J Mathijssen; Rosalinde Masereeuw; Kitty Verbeek; J Maurice Lavergne; Jean-Marc Costa; Waander L van Heerde; Irena R O Nováková
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

8.  Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.

Authors:  B A Konkle; L S Ebbesen; E Erhardtsen; R P Bianco; T Lissitchkov; L Rusen; M A Serban
Journal:  J Thromb Haemost       Date:  2007-09       Impact factor: 5.824

9.  Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Authors:  M Morfini; G Auerswald; R A Kobelt; G F Rivolta; J Rodriguez-Martorell; F A Scaraggi; C Altisent; J Blatny; A Borel-Derlon; V Rossi
Journal:  Haemophilia       Date:  2007-09       Impact factor: 4.287

10.  Successful treatment of canine hemophilia by continuous expression of canine FVIIa.

Authors:  Paris Margaritis; Elise Roy; Majed N Aljamali; Harre D Downey; Urs Giger; Shangzhen Zhou; Elizabeth Merricks; Aaron Dillow; Mirella Ezban; Timothy C Nichols; Katherine A High
Journal:  Blood       Date:  2008-12-23       Impact factor: 22.113
View more
  3 in total

1.  Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; SubbaRao V Madhunapantula; Jerry Grandoni; L Vijaya Mohan Rao
Journal:  Thromb Haemost       Date:  2019-05-26       Impact factor: 5.249

2.  Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells.

Authors:  Ernst Böhm; Birgit K Seyfried; Michael Dockal; Michael Graninger; Meinhard Hasslacher; Marianne Neurath; Christian Konetschny; Peter Matthiessen; Artur Mitterer; Friedrich Scheiflinger
Journal:  BMC Biotechnol       Date:  2015-09-18       Impact factor: 2.563

3.  Inactivation of factor VIIa by antithrombin in vitro, ex vivo and in vivo: role of tissue factor and endothelial cell protein C receptor.

Authors:  Rit Vatsyayan; Hema Kothari; Nigel Mackman; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.